Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynasty-Breast01: DB-1303 vs T-DM1 in HER2-positive Breast Cancer
NCT06265428Phase 3Active, not recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan in breast cancer (2 arms), sponsored by Duality Biotherapeutics. Primary endpoint: Progression Free Survival at 24 months. Started Jan 2024; status: active, not recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06265428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06265428.